PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BridgeBio Pharma, Inc. (BBIO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US10806X1028

CUSIP

10806X102

Sector

Healthcare

IPO Date

Jun 27, 2019

Highlights

Market Cap

$5.26B

EPS (TTM)

-$2.42

Total Revenue (TTM)

$217.77M

Gross Profit (TTM)

$214.08M

EBITDA (TTM)

-$350.26M

Year Range

$21.62 - $44.32

Target Price

$48.53

Short %

13.81%

Short Ratio

6.82

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
BBIO vs. ^GSPC BBIO vs. SPY BBIO vs. XBI BBIO vs. ROIV
Popular comparisons:
BBIO vs. ^GSPC BBIO vs. SPY BBIO vs. XBI BBIO vs. ROIV

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in BridgeBio Pharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%80.00%100.00%JulyAugustSeptemberOctoberNovemberDecember
-5.70%
100.76%
BBIO (BridgeBio Pharma, Inc.)
Benchmark (^GSPC)

Returns By Period

BridgeBio Pharma, Inc. had a return of -35.65% year-to-date (YTD) and -35.41% in the last 12 months.


BBIO

YTD

-35.65%

1M

16.24%

6M

-5.90%

1Y

-35.41%

5Y*

-8.99%

10Y*

N/A

^GSPC (Benchmark)

YTD

23.11%

1M

-0.36%

6M

7.02%

1Y

23.15%

5Y*

12.80%

10Y*

11.01%

Monthly Returns

The table below presents the monthly returns of BBIO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-15.06%-0.41%-9.46%-17.14%9.33%-9.57%2.45%7.32%-8.58%-8.05%15.72%-35.65%
202321.78%23.06%45.18%-12.42%-5.51%25.36%103.55%-14.57%-11.84%-1.25%10.25%40.61%429.79%
2022-40.83%-20.97%30.13%-20.99%-14.84%32.94%-4.63%21.25%-5.33%4.93%-10.16%-18.68%-54.32%
2021-20.18%24.52%-12.85%-9.22%5.87%2.97%-12.32%-6.25%-6.47%5.36%-17.98%-58.81%-76.54%
2020-1.60%-7.57%-9.03%5.28%-3.93%11.18%-13.71%6.11%25.65%2.29%30.90%41.54%102.88%
2019-2.11%8.82%3.85%-29.56%5.31%28.26%20.86%27.22%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BBIO is 21, meaning it’s performing worse than 79% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BBIO is 2121
Overall Rank
The Sharpe Ratio Rank of BBIO is 1818
Sharpe Ratio Rank
The Sortino Ratio Rank of BBIO is 1919
Sortino Ratio Rank
The Omega Ratio Rank of BBIO is 2020
Omega Ratio Rank
The Calmar Ratio Rank of BBIO is 1919
Calmar Ratio Rank
The Martin Ratio Rank of BBIO is 2828
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for BBIO, currently valued at -0.58, compared to the broader market-4.00-2.000.002.00-0.581.90
The chart of Sortino ratio for BBIO, currently valued at -0.60, compared to the broader market-4.00-2.000.002.004.00-0.602.54
The chart of Omega ratio for BBIO, currently valued at 0.93, compared to the broader market0.501.001.502.000.931.35
The chart of Calmar ratio for BBIO, currently valued at -0.47, compared to the broader market0.002.004.006.00-0.472.81
The chart of Martin ratio for BBIO, currently valued at -0.90, compared to the broader market0.0010.0020.00-0.9012.39
BBIO
^GSPC

The current BridgeBio Pharma, Inc. Sharpe ratio is -0.58. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of BridgeBio Pharma, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.58
1.90
BBIO (BridgeBio Pharma, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


BridgeBio Pharma, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-64.09%
-3.58%
BBIO (BridgeBio Pharma, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the BridgeBio Pharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BridgeBio Pharma, Inc. was 92.80%, occurring on May 11, 2022. The portfolio has not yet recovered.

The current BridgeBio Pharma, Inc. drawdown is 64.09%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.8%Feb 9, 2021317May 11, 2022
-65.45%Dec 24, 201958Mar 18, 2020175Nov 24, 2020233
-44.53%Sep 4, 201931Oct 16, 201925Nov 20, 201956
-21.99%Jan 4, 202117Jan 27, 20218Feb 8, 202125
-16.79%Nov 25, 20192Nov 26, 20198Dec 9, 201910

Volatility

Volatility Chart

The current BridgeBio Pharma, Inc. volatility is 20.26%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
20.26%
3.64%
BBIO (BridgeBio Pharma, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of BridgeBio Pharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for BridgeBio Pharma, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab